A team of researchers conducted genetic analyses of children and adolescents with primary adrenal insufficiency of unknown etiology to provide insight into diagnosing this and other related conditions.
A team of investigators conducted a phase 3, multicenter study with a double-blind, randomized withdrawal period to assess the effects of twice-daily osilodrostat in patients with Cushing disease.
A team of investigators reviewed data from the 2018 Nationwide Inpatient Sample to assess the impact of obesity on outcomes in patients hospitalized for adrenal insufficiency.
BBP-631 is an adeno-associated virus 5 (AAV5) gene therapy designed to deliver a functional copy of the 21-hydroxylase gene to restore the body’s ability to produce cortisol and aldosterone.
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
Patients with resistant hypertension and hypokalemia are likely to have primary aldosteronism, which may be at the root of their condition. Screening rates patients for primary aldosteronism doesn’t appear to be common practice.
Several research studies presented at ENDO 2021 have evaluated the molecular mechanisms underlying Cushing syndrome to facilitate earlier diagnosis and improve disease management.
Cardiovascular disease is the leading cause of death in patients with adrenal insufficiency. In this study, UK researchers weighed the presence of comorbidities against cardiovascular morbidity and mortality.
The goal of this study was to evaluate 11-oxyandrogens in discriminating good vs poor disease control in 21OHD in the setting of discrepant 17OHP and A4.
Patients with apparent treatment-resistant hypertension are rarely tested for primary aldosteronism.
Hydrocortisone granules delivered accurate drug dosing to effectively treat pediatric adrenal insufficiency.